Positron Emission Tomography With Fluoro-2-deoxy-D-glucose (FDG-PET) in the Staging of Post Transplant Lymphoproliferative Disorder in Lung Transplant Recipients
Positron Emission Tomography With Fluoro-2-deoxy-D-glucose (FDG-PET) in the Staging of Post Transplant Lymphoproliferative Disorder in Lung Transplant Recipients
复制标题
氟-2-脱氧-D-葡萄糖 (FDG-PET) 正电子发射断层扫描在肺移植受者移植后淋巴增殖性疾病分期中的应用
DOI：
10.1097/00005382-200404000-00002
复制
发表时间：
2004
影响因子：
3.3
通讯作者：
R. Coleman
中科院分区：
文献类型：
--
作者：
E. Marom;H. McAdams;K. Butnor;R. Coleman
移植后淋巴组织增生性疾病（PTLD）是一种组织学异质性疾病，使4 - 8%的肺移植受者并发。疾病程度是一个重要的预后因素，并可能影响治疗。正电子发射断层扫描与氟-2-脱氧-D-葡萄糖（FDG-PET）已被证明是有用的分期高级别淋巴瘤，但分期低级别和淋巴结淋巴瘤的准确性较低。本研究探讨了我们使用FDG-PET成像对肺移植受者移植后淋巴组织增生性疾病进行分期的初步经验。FDG可以显示摄取病灶，特别是在胸外部位，这是常规成像所看不到的，这允许更准确地对疾病进行分期，从而产生有用的预后信息和指导治疗。
Posttransplantation lymphoproliferative disorder (PTLD) is a histologic heterogeneous disease that complicates 4 to 8% of lung transplant recipients. Disease extent is an important prognostic factor and may affect therapy. Positron emission tomography with fluoro-2-deoxy-D-glucose (FDG-PET) has proven useful for staging high-grade lymphomas but is less accurate for staging low-grade and extranodal lymphoma. This study examined our initial experience using FDG-PET imaging to stage lung transplant recipients with posttransplantation lymphoproliferative disorder. FDG can show foci of uptake, particularly in extrathoracic sites, not seen by conventional imaging, which allows more accurate staging of disease thereby yielding useful prognostic information and guiding therapy.